CClinicalTrials.gg
Active, not recruitingNCT05174871TRansFormUpdated Mar 23, 2026

Time-Restricted Feeding in Children and Adolescents With Obesity

An interventional study of Lifestyle intervention and TRF intervention in Obesity, Childhood and Obesity, Adolescent, sponsored by Fundació Sant Joan de Déu. Active, not recruiting at 1 site in Spain. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Fundació Sant Joan de Déu · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
8 Years to 18 Years
Sex
All
01

Study summary

This study will evaluate the effectiveness of a 2-month time-restricted feeding (TRF) intervention in children and adolescents with obesity. The investigators will determine whether the potential beneficial effects of the intervention in this population are maintained over time. Furthermore, potential mechanisms mediating TRF effects will be explored, specifically focusing on the potential role of the gut microbiome and the circadian rhythm.

02

Conditions studied

  • Obesity, Childhood
  • Obesity, Adolescent

Keywords

  • Obesity
  • Time restricted feeding
03

In context

Pediatric Obesity

1,117 studies on the registry are indexed under Pediatric Obesity; 189 are open to participants now.

This study's enrollment of 67 is below the median of 103 across 862 interventional studies indexed under Pediatric Obesity.

Browse Pediatric Obesity studies →

Lead sponsor

Fundació Sant Joan de Déu is the lead sponsor of 68 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Obesity (BMI z score > 2)

Exclusion criteria

Exclusion Criteria:

  • Bariatric surgery
  • Spontaneous time-restricted feeding for > 12 hours
  • Diabetes with insulin treatment
  • Pregnancy
  • Intellectual disability
  • Under drug treatment with a prescription change in the last 3 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Active comparator
    Active control

    Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months

    Behavioral: Lifestyle intervention

  • Experimental
    Time-Restricted Feeding

    Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months. During this time, participants will have their feeding time restricted to 8 hours per day.

    Behavioral: Lifestyle intervention · Behavioral: TRF intervention

Interventions

  • BehavioralLifestyle intervention

    Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.

  • BehavioralTRF intervention

    Food intake restricted to 8 hours per day during the window between 10h and 22h. Time restricted feeding will take place 6 days per week, with the seventh day unrestricted. The intervention will last for 2 months.

06

What researchers measure

Primary outcomes

  1. Change in BMI z score

    Weight and height will be combined to calculate BMI. The World Health Organization growth charts will be used to calculate BMI z scores.

    Time frame: Baseline, 2 months

Secondary outcomes

  1. Change in BMI z score (follow-up)

    Weight and height will be combined to calculate BMI. The World Health Organization growth charts will be used to calculate BMI z scores.

    Time frame: 1 year, 2 year

  2. Change in Adiposity

    Adiposity will be measured by bioimpedance

    Time frame: Baseline, 2 months, 1 year, 2 year

  3. Change in glucose metabolism

    Fasting blood test will performed at each time point to analyze glucose metabolism, including glucose, HbA1c, and insulin levels.

    Time frame: Baseline, 2 months, 1 year, 2 year

  4. Change in lipid profile

    Fasting blood test will performed at each time point to analyze the lipid profile, including triglycerides, total cholesterol, LDL-cholesterol, and HDL-cholesterol.

    Time frame: Baseline, 2 months, 1 year, 2 year

  5. Change in blood pressure

    Both systolic and diastolic blood pressure will be measure at every time point

    Time frame: Baseline, 2 months, 1 year, 2 year

  6. Change in dietary composition

    A 4-day food registry will be analyzed at every time point to determine daily energy, macronutrient and micronutrient intake.

    Time frame: Baseline, 2 months, 1 year, 2 year

Other outcomes

  1. Change in gut microbiota

    Fecal samples will be obtained at every time-point and gut microbiota composition analyzed.

    Time frame: Baseline, 2 months, 1 year, 2 year

  2. Change in circadian rhythm

    The circadian rhythm will be measured with an ActTrust actigraph (Condor Instruments) that participants will wear for 2 weeks before each time point.

    Time frame: Baseline, 2 months, 1 year, 2 year

07

Study locations

1 site
  • Hospital Sant Joan de Deu
    Barcelona, Barcelona 08950, Spain
08

References and documents

Publications

  • Molina-Giraldo P, Murillo S, Meis L, Sans O, Amat-Bou M, Llobet M, Jimenez-Chillaron JC, Ramon-Krauel M, Lerin C. A time-restricted feeding intervention in children and adolescents with obesity: The TRansForm study protocol. Front Nutr. 2022 Oct 26;9:1026694. doi: 10.3389/fnut.2022.1026694. eCollection 2022. PubMed 36386926 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05174871
Lead sponsor
Fundació Sant Joan de Déu
Responsible party
Sponsor
First posted
Jan 3, 2022
Start date
Jan 4, 2022
Primary completion
May 31, 2023
Completion
Jun 30, 2026 (estimated)
Last update
Mar 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion